Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144542 · ClinicalTrials.gov registry record · NA
Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
A NA study of Lung Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT05144542: Active NA study of Lung Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT05144542 is a NA study of Lung Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 140 participants, below the 5,040-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144542, a NA study of Lung Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching smokers at high risk for lung cancer to electronic cigarettes. This research also may help inform the Food and Drug Administration (FDA) how best to regulate e-cigarettes with the goal of improving public health.
Primary Outcome
Mean cigarettes per day during the week of baseline combustible cigarette smoking and during the final week of electronic cigarette provision (week 27)
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Nicotine Replacement
- PROCEDURE Participants smoke their usual brand of cigarettes for 26 weeks.
- PROCEDURE Participants will vape electronic cigarettes for 26 weeks.
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2026-10-17 |
| Phase | NA |
What the registry record for NCT05144542 still lists
NCT05144542 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 5,040-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT05144542 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05144542 about?
NCT05144542 is a clinical study titled "Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer". This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators o...
What is the current status of trial NCT05144542?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2022-03-07. Estimated completion is 2026-10-17.
What conditions does trial NCT05144542 study?
This clinical trial studies the following conditions: Lung Carcinoma.
What interventions are being tested in trial NCT05144542?
The interventions under investigation include: Questionnaire Administration (OTHER), Nicotine Replacement (DRUG), Participants smoke their usual brand of cigarettes for 26 weeks. (PROCEDURE), Participants will vape electronic cigarettes for 26 weeks. (PROCEDURE).
Who is sponsoring clinical trial NCT05144542?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05144542 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05144542's enrollment target sits among peer trials
140 17th of 38 higher than 22 of 38 other Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
RECRUITING · NA
-
CONNECTing to LungCare
RECRUITING · NA
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study
RECRUITING · NA
-
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI